Browse the evidence

Fixed-ratio combinations (FRCs) of basal insulin and GLP-1 receptor agonists are indicated for patients with type 2 diabetes who are inadequately controlled on oral antihyperglycemic drugs (OADs) with an HbA1c less than 10% and within 2% of their glycemic goal, or for those already on basal insulin who remain above goal.

If you are taking oral diabetes medications but your blood sugar is still too high (HbA1c less than 10% and within 2% of your target), or if you are already on basal insulin but your levels are still above goal, ask your doctor about a fixed-ratio combination (FRC). These are single injections that combine a long-acting insulin with a GLP-1 medication. They are designed to lower blood sugar effectively, minimize weight gain, and reduce the number of injections you need to manage compared to traditional basal-bolus therapy.

For patients with Type 2 Diabetes requiring basal insulin, a glycated hemoglobin (HbA1c) goal of less than 7% is appropriate, whereas a goal of less than 6.5% is less likely to be appropriate due to increased risks of hypoglycemia and weight gain.

If you are on basal insulin, aim for an HbA1c of less than 7%. Trying to get it below 6.5% when you are on insulin can increase your risk of dangerous low blood sugar and weight gain without providing significant additional long-term benefits. Your doctor should adjust your goal based on your specific health situation, but <7% is generally the safe target for insulin users.

Orforglipron significantly improves lipid profiles, including reductions in total cholesterol, LDL cholesterol, and triglycerides, along with increases in HDL cholesterol, independent of weight loss magnitude.

Orforglipron not only helps with weight loss but also significantly improves heart health markers. It lowers bad cholesterol (LDL) and triglycerides while raising good cholesterol (HDL). These improvements occur alongside weight loss and contribute to a lower risk of cardiovascular disease, making it a comprehensive treatment for obesity-related metabolic risks.

Treatment with extended-release naltrexone/bupropion (NB) produces weight loss that is disproportionately derived from fat mass rather than lean mass compared to placebo, resulting in a favorable shift in the lean-to-fat mass ratio.

If you are using naltrexone/bupropion for weight loss, the medication helps you lose more fat and preserve more muscle than dieting alone. This is beneficial for long-term metabolic health. Ensure you are following a caloric deficit and staying active as instructed.

Monogenic obesity caused by leptin deficiency can be effectively treated with recombinant leptin therapy, restoring normal appetite regulation.

This intervention is not for the general population. It applies only to a tiny fraction of individuals with confirmed monogenic leptin deficiency. Standard weight loss strategies remain the primary approach for >99% of cases.

Effective obesity medications (e.g., GLP-1/GIP agonists) work by lowering the adipose mass set point through counteracting adaptive hormonal responses, allowing homeostasis at a lower weight, but require lifelong use to maintain this new set point.

Obesity medications are not a temporary fix but a long-term management tool for a chronic disease. They work by resetting your body's biological 'thermostat' to a lower weight. If you stop taking them, your biology will fight to regain the weight. Therefore, these medications should be viewed as lifelong treatments, similar to blood pressure medication, to maintain your health.

GLP-1 receptor agonists (GLP-1RAs) reduce binge eating frequency and severity in patients with Binge Eating Disorder (BED) and Bulimia Nervosa (BN), likely by modulating central reward circuits and increasing satiety.

If you have BED or BN, GLP-1RAs like semaglutide or liraglutide can significantly reduce binge eating episodes by changing how your brain responds to food rewards and increasing fullness. This is supported by systematic reviews, though it is not a standalone cure and should be monitored by a clinician, especially given potential gastrointestinal side effects.

GLP-1 receptor agonists (semaglutide, tirzepatide) are highly effective pharmacologic interventions for obesity, producing significant weight loss and metabolic improvements, but their rapid expansion raises safety concerns regarding gastrointestinal side effects, rare serious adverse events, and long-term outcomes not captured in clinical trials.

GLP-1 medications like semaglutide and tirzepatide are currently the most effective non-surgical treatments for obesity, offering weight loss comparable to surgery for many. However, they are not without risks, including common gastrointestinal issues and rare serious side effects. It is crucial to use these medications under strict medical supervision, especially if you have other health conditions, to manage side effects and monitor for long-term safety.

Fixed-ratio combinations (FRCs) of basal insulin and GLP-1 receptor agonists (GLP-1RA) provide superior glycemic control and weight loss compared to either component alone, but are limited by a low GLP-1RA dose relative to the insulin dose, making separate dosing preferable for obese patients requiring higher GLP-1RA doses.

Fixed-ratio combinations (like IDegLira, iGlarLixi, or IcoSema) are effective for lowering blood sugar and weight compared to using just insulin or just a GLP-1 drug. However, because the ratio of insulin to GLP-1 drug is fixed, these combinations often deliver too little GLP-1 drug for obese patients who need higher doses for maximum weight loss and glucose control. If you are obese or need high doses of GLP-1RA, separate injections of basal insulin and GLP-1RA allow you to titrate each drug independently to your optimal dose.

Antiobesity medications (AOMs) improve cardiovascular outcomes, hypertension, and metabolic liver disease in older adults, but their use requires caution due to an increased risk of sarcopenia.

For older adults, AOMs are a powerful tool to treat obesity-related health issues like heart disease and diabetes. However, because losing weight can also lead to muscle loss (sarcopenia), these medications should be used cautiously and monitored closely by a doctor, often alongside lifestyle changes.

The presence of obesity-related complications (e.g., Type 2 Diabetes, Hypertension) significantly amplifies medical costs, with costs up to 5.2 times higher for those with multiple complications compared to obesity alone.

Having obesity-related complications like Type 2 Diabetes or Hypertension drastically increases medical costs (up to 5.2x). This underscores the importance of not just losing weight, but also managing these specific conditions to control overall healthcare spending.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces Obstructive Sleep Apnea (OSA) severity (measured by AHI) and improves cardiometabolic risk factors in patients with obesity and moderate-to-severe OSA.

If you have obesity and moderate-to-severe sleep apnea, Tirzepatide is a newly approved medication that can significantly reduce the severity of your apnea (AHI) and improve blood pressure and inflammation. It works primarily by promoting weight loss and potentially affecting brain pathways related to breathing control. Because stopping the drug leads to weight regain, it is likely a long-term treatment. It is not a substitute for PAP therapy in all cases, but it is a powerful new tool, especially for those who struggle with CPAP adherence.

Achieving diabetes remission in type 2 diabetes patients reduces the risk of cardiovascular disease by approximately 30% compared to non-remission, independent of significant weight loss.

For patients with type 2 diabetes, achieving remission (normal blood glucose without medication) is a critical goal for preventing heart disease. This benefit exists even if you do not lose significant weight, suggesting that metabolic improvements (like reduced liver/pancreas fat) are key. Focus on achieving remission through available treatments rather than solely on weight loss metrics.

Habitual endurance or resistance exercise training enhances insulin-stimulated glycogen synthesis in primary human skeletal muscle stem cells compared to sedentary controls, but does not confer intrinsic protection against fatty acid-induced insulin resistance.

If you are highly active, your skeletal muscle cells are better at storing glucose as glycogen when insulin is present, regardless of whether you primarily do cardio or weight training. However, this cellular adaptation does not appear to protect your muscle cells from the negative effects of high fat exposure in a lab setting. To maximize metabolic health, maintain high activity levels, but be aware that cellular adaptations to training may not fully shield you from all metabolic insults like high lipid loads.

Treatment with maximal-tolerated dose tirzepatide (10-15 mg weekly) for 72 weeks produces substantial weight loss and health risk reduction, but typically fails to return average Class II obese individuals to the healthy BMI (<25 kg/m2) or healthy Body Roundness Index (BRI) ranges.

If you are taking tirzepatide at a high dose, expect significant health improvements and weight loss, but do not expect to automatically reach a 'healthy' BMI of under 25. The average patient in the major trials remains in the overweight or obese category even after a year. Focus on the reduction in health risks (like visceral fat/BRI) rather than just hitting a specific BMI number.

Semaglutide 2.4 mg weekly significantly improves symptoms, functional capacity, and reduces systemic inflammation in obese patients with heart failure with preserved ejection fraction (HFpEF).

If you have heart failure with preserved ejection fraction and are obese, ask your doctor about semaglutide. It is a once-weekly injection that has been shown to significantly improve your heart failure symptoms, exercise capacity, and reduce inflammation. While it may cause temporary stomach issues, the benefits for your heart and weight are substantial.

Genetic variation in the NBEA gene predicts weight loss response to GLP-1 receptor agonists (GLP-1RAs), with specific NBEA scores identifying individuals likely to be highly responsive or non-responsive to treatment.

If you are prescribed a GLP-1RA like semaglutide or liraglutide, ask your doctor about genetic testing for the NBEA gene. This test can predict whether you are likely to lose significant weight (top 20% responders) or not respond at all. This helps avoid wasting time and money on medications that are unlikely to work for your specific biology, allowing for a more personalized and effective obesity treatment plan.

Achieving ≥20–25% early postoperative weight loss (EWL) within the first 3–6 months after bariatric surgery strongly predicts sustained long-term weight loss (≥50% EWL) and metabolic remission.

If you had bariatric surgery, your weight loss in the first 3-6 months is a major predictor of your long-term success. Aim for at least 20-25% excess weight loss in this window. If you are slower, do not give up; this is a signal for your medical team to intensify support (nutrition, behavioral therapy, or medication) to help you catch up.

Semaglutide 2.4 mg is recommended for secondary prevention of cardiovascular events in individuals with BMI ≥27 kg/m² without diabetes but with established cardiovascular disease.

If you have established heart disease, are overweight (BMI ≥27), and do not have diabetes, ask your doctor about semaglutide 2.4 mg. This medication is recommended to help prevent future heart attacks, strokes, and cardiovascular death.

Caloric restriction interventions restore gut-brain axis communication in obesity by enriching beneficial bacteria (e.g., Akkermansia muciniphila), reducing LPS-mediated endotoxemia, and modulating SCFA production to enhance satiety signaling.

To leverage the gut-brain axis for weight management, reduce your daily caloric intake by 20-40% while ensuring you get adequate nutrients. This specific type of dietary restriction has been shown to improve gut bacteria diversity, reduce inflammation, and boost satiety hormones, making it easier to maintain energy balance.

Obesity is associated with gut microbiota dysbiosis characterized by reduced diversity, altered taxonomic abundance, and impaired gut-brain axis communication, leading to dysregulated appetite and energy homeostasis.

Obesity is linked to changes in gut bacteria that disrupt signals for hunger and fullness. These changes include lower bacterial diversity and reduced production of satiety hormones. Understanding this link highlights why dietary changes can help reset these signals.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and SGLT2 inhibitors reduce cardiovascular events and improve liver histology in MASLD patients, particularly those with type 2 diabetes or obesity.

If you have MASLD and diabetes or obesity, ask your doctor about GLP-1 agonists (like semaglutide) or SGLT2 inhibitors. These drugs not only help control blood sugar and weight but also significantly lower the risk of heart attacks and strokes, and may improve liver health. They are safe for use in MASLD patients within their approved indications.

Excess adiposity (BMI ≥30) is a causal risk factor for gastrointestinal cancers, increasing incidence and mortality through endocrine, inflammatory, and mechanical pathways.

Maintain a healthy weight to reduce your risk of gastrointestinal cancers. If you are overweight, consult your doctor about structured weight loss strategies, as obesity increases cancer risk and complicates surgical outcomes.

Semaglutide significantly reduces the risk of atrial fibrillation (AF) and sinus node dysfunction in patients with overweight or obesity.

If you have overweight or obesity and are concerned about heart rhythm issues like atrial fibrillation, semaglutide therapy (up to 2.4 mg) has been shown in large studies to significantly lower that risk. This benefit appears particularly strong in patients over 60 and those treated for more than a year.